Novel Therapeutic for SAH

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$249,686.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS061456-01
Agency Tracking Number:
NS061456
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
COGNOSCI, INC.
COGNOSCI, INC., 79 T. W. Alexander Drive, RESEARCH TRIANGLE PARK, NC, 27709
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
141881727
Principal Investigator:
DALE CHRISTENSEN
(919) 765-0028
DCHRISTENSEN@COGNOSCI.COM
Business Contact:
(919) 765-0028
mikevitek@cognosci.com
Research Institution:
n/a
Abstract
DESCRIPTION: Subarachnoid Hemorrhage (SAH) is a form of stroke that occurs in nearly 40,000 patients each year in the United States. Despite advances in early diagnosis and management, SAH remains a frequent cause of death and disability. In particular, va sospasm is the most common medical complication of subarachnoid hemorrhage, and often leads to further stroke and added death and disability. This disability is the result of ischemic injury due to the lack of oxygen transport to the brain following vasosp asm. Although vasospasm remains the most important cause of mortality and neurological morbidity in patients initially surviving aneurismal SAH, no effective treatment has been developed to reduce the frequency of, or to reduce the damage from this complic ation. Cognosci has recently developed novel apoE-based therapeutics that cross the blood brain barrier and exert neuroprotective and anti-inflammatory activities. One of these compounds, COG1410 has been evaluated in a clinically relevant mouse model of S AH increased survival rates, reduced the occurrence of vasospasm and improved neurological outcome (GAO Et Al. 2006, Mesis et al. 2006). We now propose to further evaluate COG1410 for treatment of SAH by determining if the compound will reduce vasospasm in a rabbit model of vasospasm and to investigate a possible mechanism by which this action may occur. We further propose to evaluate COG1410 in two in vitro models to assess genotoxicity and cardiotoxicity. Successful completion of these studies will provid e proof of principle that COG1410 has the desired characteristics in inhibition of vasospasm following SAH and that the compound is free from toxic effects that are routinely evaluated using in vitro assays. This proof of principle with then for the basis for initiation of toxicology studies during the Phase II granting period that will be designed to determine the in vivo safety profile for COG1410 so that an Investigational New Drug (IND) application can be filed with the FDA to initiate human clinical tr ials for this important orphan indication.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government